An open label, single centre, phase II pilot study to determine the pathological response rate to 12 weeks of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma

Trial Profile

An open label, single centre, phase II pilot study to determine the pathological response rate to 12 weeks of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Results (data cut-off: 18th April 2017) presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Results from this trial presented at the 2017 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain, according to a Novartis media release.
    • 28 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 May 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top